Background: Little is known about the prevalence of co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in the post-conflict South-Kivu Province, Eastern Democratic Republic of the Congo. Therefore, we aimed to determine such data at Panzi Referral Hospital. Methods: We conducted a cross-sectional study of 198 HIV-positive patients seen in consultation from June to 31 November 2017. Socio-demographic and clinical data were collected by interview and clinical examination. Blood sample was taken for serological analyses. The presence of HBV serological markers was determined by enzyme linked immunoassay (ELISA) tests. CD4+ T cell counts were determined for all patients. Data analysis was done using the JMP 7.1 software. Proportions were compared using a Chi-square test or Fisher test.
Introduction
Chronic hepatitis B virus (HBV) infection is present in 2.7 million of the 36.7 million people infected with the human immunodeficiency virus (HIV) worldwide [1] . The overall prevalence of HIV/HBV co-infection is estimated at 7.4% with 1.96 million co-infected persons (71%) living in Sub-Saharan Africa [1] .
This prevalence varies with rates estimated to be between 5% and 10% in regions such as North America, Europe and Australia compared to higher rates, between 20% and 30%, in Sub-Saharan Africa and Asia where more than 70% of the 36.7 million people infected with HIV live [1] [2] . HIV/HBV co-infection is common because of the shared transmission routes for these two viruses, including the parenteral route, the mother-child route and the sexual route. This co-infection has become one of the morbidity and mortality factors including the rapid progression of hepatic lesions to cirrhosis and for hepatocellular carcinoma associated with HBV infection compared to mono-infected HIV or HBV patients [3] . Although the specific mechanisms through which HBV interacts with HIV to influence the progression of the disease are not clearly understood up today, HIV/HBV co-infection has been identified as being responsible for higher levels of HBV replication and decreased spontaneous clearance of HBV with a higher risk of reactivation of HBV infection and death from liver complications due to hepatic failure, cirrhosis and hepatocellular carcinoma [3] [4] [5] .
fection among blood donors with prevalences rates between 3.5% and 4.8% [7] 
Methods

Study Population
A cross-sectional study was conducted between 01 July and 31 November 2017 in an HIV outpatient care center at Panzi Referral Hospital in the post-conflict south Kivu province, DRC. This center provides primary health care services to HIV-infected individuals in outpatient settings. Convenience sampling was used to consecutively select available consenting patients to participate in this study.
A total of 225 ART treated HIV-infected patients aged > 18 years were enrolled in the center during the data collection period but only 198 (88%) participants had interpretable results.
Laboratory Diagnostic Procedures
Plasma samples were collected from HIV-infected patients with unknown HBsAg status attending for routine care. For laboratory analysis, a total of 10 mL of 
Statistical Analysis
HBV prevalence estimates were calculated with 95% confidence intervals (CI).
Sociodemographic characteristics, clinical and laboratory data were recorded in a standardized form and data were entered into an electronic database in Excel (version 10). Descriptive analyses were performed using means and proportion as well as standard deviations and 95% confidence interval where necessary. As- 
Regulatory Approval
Ethics approval was obtained from the Ethics Committee of the Catholic University of Bukavu (Reference No. UCB/CIE/NC/001/7/2017).
Results
In our study, 198 HIV-infected patients were enrolled. The median age of the study participants was 43 years old (IQR 41 -45) and 12.90% (8/62) were men.
Fourteen HIV-patients were HBsAg positive yielding a co-infection prevalence Table 1 presents the socio-demographic characteristics in mono-infected and HIV/HBV co-infected patients. There were no significant differences between the HIV mono-infected group and the HIV/HBV co-infected group in terms of age, occupation, religion, level of studies and origin. However, the prevalence of co-infection was higher in male than female patients (12.90% vs 4.41%; p = 0.0306), Clinical signs such as hepatomegaly and jaundice were very highly associated
with co-infection (p < 0.0001). Similarly, fever and splenomegaly were highly significantly associated with co-infection (p < 0.001). Also, ascites was significantly more common in patients with HIV/HBV co-infection (p < 0.05). Mono and co-infected patients did not differ in prevalence of acute diarrhea, rash and lymphadenopathy (p > 0.05).
Viral encephalitis was strongly associated with co-infection (p < 0.0001), while, all other opportunistic infections observed in this study did not differ between those with and without co-infection (Table 2 ).
Discussion
We found in HIV-infected patients, HBV prevalence of 7.07% in our study setting, which is in agreement with HIV/HBV co-infection prevalence reported progress to cirrhosis and hepatocellular carcinoma [3] .
In this cohort, the HBV contact marker (HBc antibody) was prevalent in 33.33% and 3.03% of the participants had isolated anti HBcAb. This result was higher than what was reported by others authors [33] [34] [35] . However, this prevalence was lower than that described in Rwanda by Rusine et al. [29] . The prevalence of isolated HBc antibody in HIV-infected patients ranges from 17% to 81%
and depends on the prevalence of HBV infection [34] [35] [36] [37] . We specify that 3.03% of the participants had isolated anti HBcAb. It is likely that this would be related to either to the loss of the post-contact immunization marker or the presence of the occult HBV described as the appearance of replication, HBV DNA in the liver with surface antigen of hepatitis B negative as shown by some authors [25] . A major limitation in this study is that we could not investigate occult HBV infections in participants who were HBsAg-negative but anti HBc-positive by HBV DNA PCR testing. Occult active HBV infections are thought to be common among HIV patients, with reported prevalence rates ranging from 10% -14% [38] [39] [40] and up to 89% in one study in South Africa [41] . Further research is needed to determine the prevalence of occult HBV in this group.
All patients with HBV infection were in hepatitis chronic phase (defined as being HBsAg+ and HBcAb+). Of the 14 patients, 4 subjects (28.57%) had chronic replicative hepatitis infection and more than half were non-replicative. Two patients (14.29%) were inactive carriers of HBsAg and none subject had an acute viral B infection. The absence of acute hepatitis infection in HIV-infected patients and the observation that all patients have chronic viral B infection suggests that the mode of HBV infection was during infancy and from mother to child which is the most common mode of contamination in our setting as for other developing countries would be the same mode in this group of people considered at risk as the entire general population. This hypothesis suggests that these patients [26] and in Zambia by Wandeler et al. [16] but higher than the 15% prevalence that was described in a study conducted in Uganda [17] . It was lower than the 62% reported in a second Ghana study [42] . The prevalence of chronic non-replicative infection of 57.19% in co-infected patients found in this study, the latter is higher than that of 47.9% reported in Ghana [26] and in 33.3% reported in Zambia [16] .
We observed that 36.87% of subjects were HBV immunization marker carries (defined as HBsAb positive) and in those, 68.49% had obtained immunization after HBV infection (HBcAb positive). This prevalence was similar to that reported by Boyd et al. [43] . However, it was slightly higher than the 14% to 50%
prevalence in other cohorts of co-infected treated patients [10] [14] [24] [44] but similar to that between 50% and 71% in patients infected with HBV alone [31] [45] [46] . Also, these prevalences data are higher than those reported from Maputo, where less than 1% of co-infected subjects carried the marker for HBV immunization [23] . This loss of immunity against hepatitis B was explained by the fact that HIV infection leads to immunosuppression which would reduce the reaction.
Male sex was associated to co-infection significantly with co-infection as has been reported in Benin [28] , Nigeria [31] , South Africa [27] , Rwanda [29] and Cameroon [19] . Other authors have reported a female predominance in Mozambique and Zambia [16] [23], Uganda [17] , and in South Kivu [12] . In observing our study population, there were a large number of female than male patients. But by observing HIV/HBV co-infection, female subjects were less infected than male subjects. The higher proportion of women in our setting may be due to the higher accessibility of primary health care to women compared to men or other undocumented factors in our study.
In this study, the average age of co-infected patients was 44 ± 12 years. The 2008 South African study reported a similar average age of 41 years [27] . However, studies in Uganda, Kenya, Rwanda and Mozambique reported a much lower average age [14] [16] [17] [29] . These differences in average age could be due on the one hand to the introduction of the HBV vaccination program in some countries which would have significantly reduced the disease in younger age groups; and on the other hand to a recent introduction in the expanded immunization in children as is the case of our country or the absence of that program.
We also found that the majority (52.53%) of the patients in our study were in the WHO clinical I/II stage, but WHO clinical stage III/IV patients were more likely to be HIV/HBV co-infected (10.64%). Similarly, we observed that the degree of immunosuppression was more severe in co-infected subjects (50.00%) than in non-co-infected subjects (17.93%). (75%) of the subjects were in WHO clinical stage I and II [22] , which could account for the differences of findings. Regarding the impact of HBV on the progression of HIV infection, our data showed that CD4+ T cell counts were very low in co-infected patients than in HIV-infected patients alone. Previous studies have failed to demonstrate that HBV may accelerate or aggravate the natural history of HIV infection [47] . However, due to the cross-sectional design of our study, our data are subject to reverse causation limitation preventing us to assess the impact of HBV on HIV disease progression. Well-designed prospective studies are needed to derive these conclusions.
Conclusion
We found that the prevalence of HIV/HBV co-infection was 7.07% and all patients had chronic HBV infection. This study reinforces the importance of integrating HBV screening programs into HIV routine care to reduce morbidity and mortality levels caused by HIV/HBV co-infection.
